FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987338462> ?p ?o ?g. }

• W1987338462 endingPage "255" @default.
• W1987338462 startingPage "247" @default.
• W1987338462 abstract "Journal of Clinical Pharmacy and TherapeuticsVolume 15, Issue 4 p. 247-255 Free Access THERAPEUTIC PROGRESS–REVIEW XXXVIII: ARE WE MAKING PROGRESS IN THE TREATMENT OF PROSTATE CANCER? T. W. Carr, Corresponding Author T. W. Carr Department of Urology, Queen Elizabeth Hospital, Birmingham, U.K.Senior Registrar in Urology, Department of Urology, Queen Elizabeth Hospital, Birmingham, U.K.Search for more papers by this author T. W. Carr, Corresponding Author T. W. Carr Department of Urology, Queen Elizabeth Hospital, Birmingham, U.K.Senior Registrar in Urology, Department of Urology, Queen Elizabeth Hospital, Birmingham, U.K.Search for more papers by this author First published: August 1990 https://doi.org/10.1111/j.1365-2710.1990.tb00382.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 OPCS (Office of Population Census Surveys) (1988) Medical Quarterly Statistics 610, OPC. 2 J. Waterhouse (ed.) (1982) Cancer incidence in Five Continents Vol VI.)World Health Organisation International Agency for Research on Cancer and International Association of Cancer Registries. I ARC Scientific Publications No. 42, Lyon. 3 Franks, L.M. (1956) The natural history of prostatic cancer. Lancet, ii, 1037– 1039. 4 Cantrell, B.B., de Klerk, D.P., Eggleston, J.C., Boitnott, J.K. & Walsh, P.C. (1981) Pathological factors that influence prognosis in stage A prostatic cancer: The influence of extent vs grade. Journal of Urology, US, 516– 520. 5 The Veterans Administration Co-operative Urological Research Group (1968) Factors in the prognosis of carcinoma of the prostate: a cooperative study. Journal of Urology, 100, 59– 65. 6 Young, H.H. (1905) The early diagnosis and radical cure of carcinoma of the prostate. Bulletin of the Johns Hopkins Hospital, 16, 315– 321. 7 Walsh, P.C. & Jewett, H.J. (1980) Radical surgery for prostatic cancer. Cancer, 45, 1906– 1911. 8 Benson, R.C. Jr, Tomera, K.M., Zincke, H., Fleming, T.R. & Utz, D.C. (1984) Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. Journal of Urology, 131, 1103– 1106. 9 Paulson, D.F., Lin, G.H., Hinshaw, W., Stephani, S. and The Uro-oncology Research Group. (1982) Radical surgery versus radiotherapy for adenocarcinoma of the prostate. Journal of Urology, 128, 502– 504. 10 Byar, D.P. (1980) VACURG studies of conservative treatment. Scandinavian Journal of Urology and Nephrology, (Suppl. 55), 99– 102. 11 Igel, T.C., Barrett, D.M., Segura, J.W., Benson, R.C. Jr & Rife, C.C. (1987) Perioperative and postoperative complications from bilateral pelvic lymphadenectomy and radical retropubic prostatectomy. Journal of Urology, 137, 1189– 1191. 12 Walsh, P.C. & Donker, P.J. (1982) Impotence following radical prostatectomy: insight into etiology and prevention. Journal of Urology, 128, 492– 497. 13 Walsh, P.C, Epstein, J.I. & Lowe, F.C. (1987) Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. Journal of Urology, 138, 823– 827. 14 Catalona, W.J., Miller, D.R. & Kavoussi, L.R. (1988) Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. Journal of Urology, 140, 540– 543. 15 Guerriero, W.G., Carlton, C.E. & Hudgins, P.T. (1980) Combined interstitial and external radiotherapy in the definitive management of carcinoma of the prostate. Cancer, 45, 1922– 1928. 16 Grossman, H.B., Batata, M., Hilaris, B. & Whitmore, W.F. (1982) 125I implantation for carcinoma of the prostate. Urology, 10, 591– 598. 17 Byar, D.P. & Corle, D.K. (1984) Analysis of prognostic factors for prostatic cancer in the VACURG studies. In: Controlled Clinical Trials in Urologic Oncology (ed. L. Denis, G.P. Murphy, G.R. Prout & F. Schroeder), Raven Press, New York . 18 Huggins, C., Stevens, R.E. Jr & Hodges, C.V. (1941) Studies in prostate cancer. Archives of Surgery, 43, 209– 223. 19 Scott, W.W., Menon, M. & Walsh, P.C. (1980) Hormonal therapy of prostatic cancer. Cancer, 45, 1929– 1936. 20 Smith, J. A. (1987) New methods of endocrine management of prostatic cancer. Journal of Urology, 137, 1– 10. 21 The Veterans Administration Co-operative Urological Research Group (1967) Carcinoma of the prostate: treatment comparisons. Journal of Urology, 98, 516– 522. 22 Hurst, K.S. & Byar, D.P. (1973) An analysis of the effects of changes from the assigned treatment in a clinical trial of treatment for prostate cancer. Journal of Chronic Diseases, 26, 311– 324. 23 Handley, R.C., Carr, T.W., Travis, D., Powell, P.H. & Hall, R.R. (1988) Deferred treatment for prostate cancer. British Journal of Urology, 62, 249– 253. 24 Byar, D.P. (1980b) VACURG studies of post-prostatectomy survival. Scandinavian Journal of Urology and Nephrology, (Suppl. 55), 113– 116. 25 Haapiainen, R., Rannikko, S. & Alfthan, O. (1986) Comparison of primary orchidectomy with oestrogen therapy in advanced prostatic cancer. British Journal of Urology, 58, 528– 533. 26 Hendriksson, P. & Johansson, S.-E. (1987) Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. American Journal of Epidemiology, 125, 970– 978. 27 Prout, G.R., Irwin, R.J. Jr, Kliman, B. et al. (1975) Prostatic cancer and Sch 13521: II Histological alterations and the pituitary gonadal axis. Journal of Urology, 113, 834– 840. 28 Presant, C.A., Soloway, M.S., Klioze, S.S. et al. (1987) Buserelin treatment of advanced prostatic cancer. Cancer, 59, 1713– 1716. 29 Williams, G., Kerle, D., Griffin, S., Dunlop, H. & Bloom, S.R. (1984) Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system. British Medical Journal, 289, 1580– 1581. 30 Waxman, J., Man, A., Hendry, W.F. et. al. (1985) Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostate cancer. British Medical Journal, 291, 1387– 1388. 31 Labrie, F., Dupont, A., Belanger, A. et al. (1985) Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. British Medical Journal, 291, 369– 370. 32 Labrie, F., Dupont, A., Belanger A., et al (1983) New approach in the treatment of prostate cancer: complete insted of partial withdrawal of androgens. Prostate, 4, 579. 33 Labrie, F., Dupont, A., Giguere, M. et al. (1988) Benefits of combination therapy with fiutamide in patients relapsing after castration. British Journal of Urology, 61, 341– 346. 34 Crawford, D.E., Eisenberger, M.A., McLeod, D.G. et al. (1989) A controlled trial of leuprolide with and without fiutamide in prostatic carcinoma. New England Journal of Medicine, 321, 419– 424. 35 de Kernion, J.B. & Lindner, A. (1984) Chemotherapy of hormonally unresponsive prostatic carcinoma. Urologic Clinics of North America, 11, 319– 326. 36 Cooner, W.H., Mosley, B.R., Rutherford, C.L. Jr et al. (1988) Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. Journal of Urology, 139, 758– 761. 37 Ercole, C.J., Lange, P.H., Mathisen, M. et al. (1987) Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. Journal of Urology, 138, 1181– 1184. 38 Daly, M.J. & Tse, A.K.O. (1987) Prostate cancer. The Pharmaceutical Journal, Feb. 28, 238, 272– 275. Volume15, Issue4August 1990Pages 247-255 ReferencesRelatedInformation" @default.
• W1987338462 created "2016-06-24" @default.
• W1987338462 creator A5023766074 @default.
• W1987338462 date "1990-08-01" @default.
• W1987338462 modified "2023-09-25" @default.
• W1987338462 title "THERAPEUTIC PROGRESS–REVIEW XXXVIII: ARE WE MAKING PROGRESS IN THE TREATMENT OF PROSTATE CANCER?" @default.
• W1987338462 cites W141613484 @default.
• W1987338462 cites W161555551 @default.
• W1987338462 cites W166500613 @default.
• W1987338462 cites W194609839 @default.
• W1987338462 cites W1983897608 @default.
• W1987338462 cites W1998726940 @default.
• W1987338462 cites W2009974996 @default.
• W1987338462 cites W2014145760 @default.
• W1987338462 cites W2015646620 @default.
• W1987338462 cites W2016016099 @default.
• W1987338462 cites W2035397440 @default.
• W1987338462 cites W2038617112 @default.
• W1987338462 cites W2067009115 @default.
• W1987338462 cites W2073148143 @default.
• W1987338462 cites W2074613446 @default.
• W1987338462 cites W2076212902 @default.
• W1987338462 cites W2081537348 @default.
• W1987338462 cites W2272670033 @default.
• W1987338462 cites W2396128216 @default.
• W1987338462 cites W2402647607 @default.
• W1987338462 cites W2409915382 @default.
• W1987338462 cites W2409949860 @default.
• W1987338462 cites W2410652919 @default.
• W1987338462 cites W2412362667 @default.
• W1987338462 cites W2415166030 @default.
• W1987338462 cites W2417023518 @default.
• W1987338462 cites W2736074889 @default.
• W1987338462 cites W2736217684 @default.
• W1987338462 cites W38427941 @default.
• W1987338462 cites W4230398659 @default.
• W1987338462 cites W44088029 @default.
• W1987338462 doi "https://doi.org/10.1111/j.1365-2710.1990.tb00382.x" @default.
• W1987338462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1699956" @default.
• W1987338462 hasPublicationYear "1990" @default.
• W1987338462 type Work @default.
• W1987338462 sameAs 1987338462 @default.
• W1987338462 citedByCount "0" @default.
• W1987338462 crossrefType "journal-article" @default.
• W1987338462 hasAuthorship W1987338462A5023766074 @default.
• W1987338462 hasBestOaLocation W19873384621 @default.
• W1987338462 hasConcept C121608353 @default.
• W1987338462 hasConcept C126322002 @default.
• W1987338462 hasConcept C143998085 @default.
• W1987338462 hasConcept C2776235491 @default.
• W1987338462 hasConcept C2780192828 @default.
• W1987338462 hasConcept C29456083 @default.
• W1987338462 hasConcept C71924100 @default.
• W1987338462 hasConceptScore W1987338462C121608353 @default.
• W1987338462 hasConceptScore W1987338462C126322002 @default.
• W1987338462 hasConceptScore W1987338462C143998085 @default.
• W1987338462 hasConceptScore W1987338462C2776235491 @default.
• W1987338462 hasConceptScore W1987338462C2780192828 @default.
• W1987338462 hasConceptScore W1987338462C29456083 @default.
• W1987338462 hasConceptScore W1987338462C71924100 @default.
• W1987338462 hasIssue "4" @default.
• W1987338462 hasLocation W19873384621 @default.
• W1987338462 hasLocation W19873384622 @default.
• W1987338462 hasOpenAccess W1987338462 @default.
• W1987338462 hasPrimaryLocation W19873384621 @default.
• W1987338462 hasRelatedWork W131936546 @default.
• W1987338462 hasRelatedWork W1497253641 @default.
• W1987338462 hasRelatedWork W1980245127 @default.
• W1987338462 hasRelatedWork W2060381175 @default.
• W1987338462 hasRelatedWork W2075763133 @default.
• W1987338462 hasRelatedWork W2088520467 @default.
• W1987338462 hasRelatedWork W2376423713 @default.
• W1987338462 hasRelatedWork W2386364393 @default.
• W1987338462 hasRelatedWork W2400504790 @default.
• W1987338462 hasRelatedWork W3032731309 @default.
• W1987338462 hasVolume "15" @default.
• W1987338462 isParatext "false" @default.
• W1987338462 isRetracted "false" @default.
• W1987338462 magId "1987338462" @default.
• W1987338462 workType "article" @default.